None listed
Conditions
Brief summary
The COSAQ trial aims to establish the impact on sleep function of using a CPAP nasal mask and pump at night. Continuous positive airway pressure (CPAP) is a nasal/facial mask and machine used at night to treat sleep apnoea. Although CPAP is the usual treatment for sleep apnoea, previous reports suggest that is poorly tolerated in acute quadriplegia. A maximum of 35% of those with chronic quadriplegia are adherent with therapy, with a higher rate of 50% in acute quadriplegia. A range of factors including severe immobility and psychological factors appear to contribute to a low acceptance of CPAP. The SHiQ COSAQ project will examine the impact on sleep function, quality of life and cognition of using CPAP, and establish whether the benefit of using CPAP is outweighed by the inconvenience of using it. People with quadriplegia have extremely high rates of sleep apnoea after injury which is undoubtedly limiting their rehabilitation. Successful treatment may improve acute, sub-acute and community outcomes for this group and demonstrate significant cost-utility.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
Acute, traumatic quadriplegia. Obstructive Sleep Apnoea confirmed on full polysomnography. Able to tolerate at least four hours of CPAP use on at least one of first three nights on which the device is trialled.
Exclusion criteria
Successful CPAP therapy for OSA prior to injury Significant head injury (Glascow Coma Score < 8 at first assessment) Ongoing hypercapnic ventilatory failure (PaCO2 > 45 mmHg at randomisation) Likely inability to be followed up until 3 months Condition likely to significantly limit CPAP use (eg major psychoses, facial or base of skull fractures, etc)